Stock Taper
Entera Bio Ltd. is a Jerusalem-based clinical-stage biopharmaceutical company developing oral large molecule therapeutics, with lead candidates in Phase II for hypoparathyroidism and osteoporosis, and collaborations with Amgen.

Entera Bio is developing the first once-daily oral teriparatide tablet for post-menopausal osteoporosis, with its lead candidate preparing for Phase 3 trials and representing the company's main commercial focus.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
AGEN | $7.66 | COMPARE |
IRD | $3.69 | COMPARE |
ABOS | $2.92 | COMPARE |
HURA | $2.11 | COMPARE |
ANIX | $3.48 | COMPARE |
SEER | $1.98 | COMPARE |
INO | $1.29 | COMPARE |
SPRO | $1.20 | COMPARE |